New England Biolabs, Inc v Commissioner of Patents

Case [2001] FCA 1551


FEDERAL COURT OF AUSTRALIA

New England Biolabs, Inc v Commissioner of Patents [2001] FCA 1551

NEW ENGLAND BIOLABS, INC v COMMISSIONER OF PATENTS & ANOR

V 910 OF 2000

EMMETT J
27 JULY 2001
SYDNEY

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

V910 OF 2000

BETWEEN:

NEW ENGLAND BIOLABS, INC
APPLICANT

AND:

COMMISSIONER OF PATENTS
FIRST RESPONDENT

F. HOFFMANN-LA ROCHE AG
SECOND RESPONDENT

JUDGE:

EMMETT J

DATE OF ORDER:

27 JULY 2001

WHERE MADE:

SYDNEY

THE COURT ORDERS THAT:

1.        The application be dismissed.

  1.        The applicant pay the respondents’ costs up to and including 10 May 2001.

3.        There be no other order as to the costs of the proceedings.

Note:    Settlement and entry of orders is dealt with in Order 36 of the Federal Court Rules.

IN THE FEDERAL COURT OF AUSTRALIA

NEW SOUTH WALES DISTRICT REGISTRY

V910 OF 2000

BETWEEN:

NEW ENGLAND BIOLABS, INC
APPLICANT

AND:

COMMISSIONER OF PATENTS
FIRST RESPONDENT

F. HOFFMANN-LA ROCHE AG
SECOND RESPONDENT

JUDGE:

EMMETT J

DATE:

27 JULY 2001

PLACE:

SYDNEY

REASONS FOR JUDGMENT

  1. On 27 June 2001, I published my reasons for reaching the conclusion that this application should be dismissed with costs.  However, I gave the parties the opportunity of considering my conclusion so that there could be further submissions as to the orders that might be appropriate in the light of the reasons that I then published.

  2. The parties are now agreed that it is appropriate that I order that the application be dismissed.  However, there has been further debate concerning the question of costs. 

  3. As I indicated in my earlier reasons, a question arose in the course of the hearing concerning compliance with the Patent Regulations 1991 (“the regulations”).  As a result of that issue being raised, an amended application was filed and further submissions were made concerning the question of whether or not there had been compliance with the regulations and what the consequences of any non-compliance would be. 

  4. There was no further oral hearing, but the matter was dealt with by means of written submissions.  Ultimately, as I have indicated, I concluded that, while there was non-compliance with the regulations, that non-compliance did not lead to any invalidity of any decision made by the Commissioner of Patents.  Each of the parties therefore has been partly successful in relation to that subsequent series of questions. 

  5. The applicant, New England Biolabs, Inc (“NEB”), initially asked that there be separate orders for costs in respect of the sub-issues that were subsequently raised, namely the compliance question and the question of the consequence of non‑compliance.  That seems to me to be an inappropriate particularisation of costs.  It would raise difficulties in terms of allocation and appropriation of costs.  However, as I have said, although ultimately NEB failed, both parties were partly successful in terms of the subsequent issues raised.

  6. In the circumstances, the appropriate course is simply to make no order as to the costs of all of the issues that were ventilated after the hearing.  What I propose is to order the applicant to pay the respondent’s costs up to and including 10 May 2001, and make no order as to any further costs in the proceedings. 

I certify that the preceding six (6) numbered paragraphs are a true copy of the Reasons for Judgment herein of the Honourable Justice Emmett .

Associate:

Dated:             2 November 2001

Counsel for the Applicant: Ms P Tate
Solicitor for the Applicant: Blake Dawson Waldron
Solicitor for the First Respondent: Australian Government Solicitor
Counsel for the Second Respondent: Mr S C G Burley
Solicitor for the Second Respondent: Sprusons Solicitors
Date of Hearing: 27 July 2001
Date of Judgment: 27 July 2001
Details
AGLC
New England Biolabs, Inc v Commissioner of Patents [2001] FCA 1551
Case
[2001] FCA 1551
Decision Date

CaseChat Overview and Summary

The case of New England Biolabs, Inc v Commissioner of Patents involved a dispute over the patentability of a particular enzyme. The applicant, New England Biolabs, Inc, sought to have a patent granted for a novel enzyme, while the Commissioner of Patents opposed the application on the grounds that the invention was not patentable. The case was heard in the Federal Court of Australia.

The central legal issues in the case were whether the enzyme in question was a "manner of manufacture" under the Patents Act, and whether the enzyme was sufficiently novel and inventive to warrant the grant of a patent. The court had to consider the relevant statutory provisions and case law in determining whether the enzyme met the criteria for patentability. The court also had to consider the evidence presented by both parties, including expert evidence, in making its decision.

In its judgment, the court held that the enzyme did not meet the criteria for patentability under the Patents Act. The court found that the enzyme was not a "manner of manufacture" as it was a naturally occurring substance that had been isolated and purified. The court also found that the enzyme was not novel or inventive, as it was already known in the art and could be readily made by a person skilled in the field. The court dismissed the application for a patent and ordered the applicant to pay the respondent's costs up to and including 10 May 2001. The court made no other order as to costs.

Orders

Orders of the court

1. The application be dismissed.

2.

The applicant pay the respondents’ costs up to and including 10 May 2001.

3. There be no other order as to the costs of the proceedings.

Background

Background to the litigation

Full text does not contain this section.

Evidence

Evidence Before The Court

Full text does not contain this section.

Decision

Reasons for decision

EMMETT J

Full text does not contain this section.

Ratio Decidendi

Legal Principle Established

Established by: EMMETT J

Full text does not contain this section.